细胞及基因治疗药物传递市场－全球及区域分析：依治疗类型、传递方式及区域－分析与预测（2025-2035）

全球细胞和基因治疗药物传输市场 - 分析与预测（2025-2035）

细胞和基因治疗药物传递是一种专门的方法，用于将含有活细胞或基因改造基因的复杂治疗方法注射到患者体内。

这个输送过程对于确保这些先进的疗法有效且安全地引入目标细胞和组织至关重要，这些疗法通常涉及修改患者的遗传物质或提供新细胞来修復或替换受损组织。

药物输送系统领域涵盖预填充註射器、输液帮浦、注射器和专用套管等设备，旨在满足这些先进疗法的独特需求。这些系统对于克服治疗的微妙性所带来的挑战至关重要，例如确保细胞和基因的稳定性、防止免疫排斥以及标靶化体内的适当部位。

整体而言，细胞和基因治疗药物传递是推动精准医疗的重要组成部分，为治疗遗传疾病、癌症和其他以前难以治疗的严重带来了新的希望。

细胞和基因疗法药物传输市场的主要驱动力之一是慢性病和遗传疾病（尤其是癌症、糖尿病和罕见遗传疾病）的盛行率不断上升。随着这些疾病的日益普遍，对能够提供有针对性且有效治疗方法的先进治疗方法的需求也日益增长。虽然细胞和基因疗法已成为突破性的解决方案，但它们的成功在很大程度上取决于创新的药物传输装置，这些装置能够确保精准给药、最佳剂量并改善患者预后。慢性疾病患者数量的快速成长不仅刺激了这些治疗方法的采用，也加速了专用输送装置的开发和广泛应用，推动了市场的强劲成长。

细胞和基因治疗药物传输市场面临的主要挑战之一是高昂的製造和治疗成本。细胞和基因治疗药物的製造涉及复杂的活细胞和基因改造过程，需要专用设备、高技能劳动力以及大量的研发投入。这些治疗方法通常个性化，这增加了其成本。此外，用于实施这些治疗方法的专用药物输送设备，例如输液泵、预填充式注射器和专用注射器，也导致了治疗总成本的居高不下。

这项挑战限制了这些治疗方法的可及性，尤其对于资源匮乏地区和保险不足的患者而言。高昂的治疗费用可能会阻碍这些治疗方法的广泛应用，并减缓其融入全球医疗保健体系的速度。克服这些经济障碍对于让更多患者能够获得细胞和基因疗法至关重要。

全球细胞和基因治疗药物输送市场竞争激烈，几个主要企业推动创新和市场成长。诺华、辉瑞、安进公司、碧迪公司、吉利德科学（凯特製药）、百时美施贵宝和强生等主要企业公司在开发和商业化用于细胞和基因治疗的先进药物输送系统方面处于领先地位。

这些公司正在大力投资研发，以开发更有效率、可扩展且更适合患者的给药方法，旨在提高这些创新疗法的可及性和有效性。

细胞和基因治疗药物传输市场细分：

细分 1：依治疗类型

• 细胞疗法
• 基因治疗

细分 2：依交付方式

• 体内
• 体外

细分3：按地区

• 北美洲
• 欧洲
• 亚太地区

全球细胞和基因治疗药物传输市场最重要的新兴趋势之一是血液生物标记检测在阿兹海默症早期检测中的进展和广泛应用。这些检测提供了一种侵入性较小、经济高效且可扩展的替代方案，可取代脑脊髓液 (CSF) 分析和正子断层扫描 (PET) 等传统方法。尤其是罗氏的 Elecsys pTau217 等血液检测已证明其诊断准确性可与 PET 和 CSF 检测相媲美，标誌着临床诊断领域的一个重要里程碑。这些检测能够在阿兹海默症出现严重认知能力下降之前进行早期检测，为早期疗育提供了重要机会。

此外，血液诊断技术在临床试验中发展势头强劲，为确定合适的缓解疾病治疗候选药物提供了更便捷的方法。这一趋势不仅提高了阿兹海默症诊断的准确性，也使检测更加经济实惠、便捷易得，这对于全球推广至关重要，尤其是在医疗资源匮乏的地区。随着这些技术的不断发展和获得监管部门的核准，它们有望彻底改变阿兹海默症的检测和管理，最终改善患者的预后。

本报告研究了全球细胞和基因治疗药物输送市场，提供了市场概述、按治疗类型、输送方式和地区分類的趋势，以及参与市场的公司概况。

目录

执行摘要

第一章全球细胞和基因治疗药物传输市场：产业展望

• 介绍
• 市场趋势
• 法律规范
• 临床试验分析
• 市场动态

2. 全球细胞和基因治疗药物传输市场（按治疗类型），2023-2035

• 细胞疗法
• 基因治疗

3. 全球细胞与基因治疗药物传递市场（传递方式），2023-2035

• 体内
• 体外

4. 2023-2035年全球细胞及基因治疗药物传递市场（按地区）

• 北美洲
• 欧洲
• 亚太地区

5. 全球细胞和基因治疗药物传输市场：竞争格局和公司概况

• 关键策略和发展
• 公司简介
  • Amgen Inc.
  • Bausch & Lomb Incorporated
  • Becton, Dickinson and Company
  • Bluebird bio, Inc.
  • Castle Creek Biosciences, Inc. (Fibrocell Technologies, Inc.)
  • Dendreon Pharmaceuticals LLC
  • Helixmith Co., Ltd (ViroMed Co., Ltd)
  • Gilead Sciences (Kite Pharma)
  • Kolon TissueGene, Inc.
  • Novartis AG
  • Orchard Therapeutics plc
  • Pfizer Inc.
  • Renova Therapeutics
  • Vericel Corporation

第六章调查方法

Global Cell and Gene Therapy Drug Delivery Market, Analysis and Forecast: 2025-2035

Cell and gene therapy drug delivery is a specialized method used to administer complex therapeutic treatments, including living cells and genetically modified genes, into a patient's body. This delivery process is crucial for ensuring that these advanced therapies are effectively and safely introduced to the targeted cells or tissues. The therapies often involve modifying a patient's genetic material or providing new cells to repair or replace damaged tissues.

The drug delivery systems in this field include devices like pre-filled syringes, infusion pumps, injectors, and specialized cannulas, designed to meet the specific needs of these advanced therapies. These systems are critical for overcoming the challenges posed by the delicate nature of the therapies, such as ensuring the stability of cells and genes, preventing immune rejection, and targeting the right areas of the body.

Overall, cell and gene therapy drug delivery is an essential component of advancing precision medicine, offering new hope for the treatment of genetic disorders, cancers, and other severe diseases that were previously difficult to treat.

One of the key drivers of the cell and gene therapy drug delivery market is the increasing prevalence of chronic and genetic disorders, particularly cancer, diabetes, and rare genetic diseases. As these conditions become more widespread, there is a growing demand for advanced therapies that can offer targeted and effective treatment options. Cell and gene therapies have emerged as transformative solutions, and their success relies heavily on innovative drug delivery devices that ensure precise administration, optimal dosage, and improved patient outcomes. This surge in chronic disease cases not only fuels the adoption of these therapies but also accelerates the development and deployment of specialized delivery devices, thereby driving robust market growth

One of the primary challenges in the cell and gene therapy drug delivery market is the high cost of manufacturing and treatment. The production of cell and gene therapies involves complex processes, including the modification of living cells or genes, which requires specialized equipment, highly skilled labor, and significant research and development. These therapies are often personalized, adding to the cost. Additionally, the specialized drug delivery devices required for administering these therapies, such as infusion pumps, pre-filled syringes, and specialized injectors, also contribute to the high overall treatment cost.

This challenge limits the accessibility of these therapies, especially in low-resource settings or for patients without adequate insurance coverage. The high costs can hinder the widespread adoption of these treatments and slow down their integration into global healthcare systems. Overcoming these financial barriers is crucial to ensuring that cell and gene therapies reach a broader patient population.

The global cell and gene therapy drug delivery market is highly competitive, with several key players driving innovation and market growth. Leading companies such as Novartis, Pfizer, Amgen Inc., Becton, Dickinson and Company, Gilead Sciences (Kite Pharma), Bristol Myers Squibb, and Johnson & Johnson are at the forefront of developing and commercializing advanced drug delivery systems for cell and gene therapies.

These companies are investing heavily in research and development to create more efficient, scalable, and patient-friendly delivery methods, aiming to enhance the accessibility and effectiveness of these transformative treatments.

Cell and Gene Therapy Drug Delivery Market Segmentation:

Segmentation 1: by Therapy Types

• Cell Therapy
• Gene Therapy

Segmentation 2: by Delivery Methods

• In Vivo
• Ex Vivo

Segmentation 3: by Region

• North America
• Europe
• Asia-Pacific

One of the most significant emerging trends in the global cell and gene therapy drug delivery market is the advancement and widespread adoption of blood-based biomarker tests for the early detection of Alzheimer's disease. These tests offer a less invasive, cost-effective, and scalable alternative to traditional methods like cerebrospinal fluid (CSF) analysis and positron emission tomography (PET) scans. Notably, blood-based tests such as Roche's Elecsys pTau217 have demonstrated diagnostic accuracy comparable to PET scans and CSF assays, marking a major milestone in clinical diagnostics. These tests enable earlier detection of Alzheimer's, often before significant cognitive decline occurs, providing critical opportunities for early intervention.

Furthermore, blood-based diagnostics are gaining momentum in clinical trials, offering a more accessible way to identify suitable candidates for disease-modifying treatments. This trend is not only increasing the accuracy of Alzheimer's diagnoses but also improving the affordability and accessibility of testing, which is crucial for global adoption, particularly in underserved regions. As these technologies continue to evolve and gain regulatory approval, they are expected to revolutionize Alzheimer's disease detection and management, ultimately leading to better outcomes for patients.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Cell and Gene Therapy Drug Delivery Market: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Clinical Trial Analysis
• 1.5 Market Dynamics
  • 1.5.1 Impact Analysis
  • 1.5.2 Market Drivers
  • 1.5.3 Market Challenges
  • 1.5.4 Market Opportunities

2. Global Cell and Gene Therapy Drug Delivery Market (Therapy Types), ($Billion), 2023-2035

• 2.1 Cell Therapy
• 2.2 Gene Therapy

3. Global Cell and Gene Therapy Drug Delivery Market (Delivery Methods), ($Billion), 2023-2035

• 3.1 In Vivo
• 3.2 Ex Vivo

4. Global Cell and Gene Therapy Drug Delivery Market (Region), ($Billion), 2023-2035

• 4.1 North America
  • 4.1.1 Key Findings
  • 4.1.2 Market Dynamics
  • 4.1.3 Market Sizing and Forecast
    • 4.1.3.1 North America Cell and Gene Therapy Drug Delivery Market, by Country
      • 4.1.3.1.1 U.S.
• 4.2 Europe
  • 4.2.1 Key Findings
  • 4.2.2 Market Dynamics
  • 4.2.3 Market Sizing and Forecast
    • 4.2.3.1 Europe Cell and Gene Therapy Drug Delivery Market, by Country
      • 4.2.3.1.1 Germany
      • 4.2.3.1.2 U.K.
      • 4.2.3.1.3 France
      • 4.2.3.1.4 Italy
• 4.3 Asia Pacific
  • 4.3.1 Key Findings
  • 4.3.2 Market Dynamics
  • 4.3.3 Market Sizing and Forecast
    • 4.3.3.1 Asia Pacific Cell and Gene Therapy Drug Delivery Market, by Country
      • 4.3.3.1.1 China
      • 4.3.3.1.2 Japan

5. Global Cell and Gene Therapy Drug Delivery Market: Competitive Landscape and Company Profiles

• 5.1 Key Strategies and Development
  • 5.1.1 Mergers and Acquisitions
  • 5.1.2 Synergistic Activities
  • 5.1.3 Business Expansions and Funding
  • 5.1.4 Product Launches and Approvals
  • 5.1.5 Other Activities
• 5.2 Company Profiles
  • 5.2.1 Amgen Inc.
    • 5.2.1.1 Overview
    • 5.2.1.2 Top Products / Product Portfolio
    • 5.2.1.3 Top Competitors
    • 5.2.1.4 Target Customers/End-Users
    • 5.2.1.5 Key Personnel
    • 5.2.1.6 Analyst View
  • 5.2.2 Bausch & Lomb Incorporated
    • 5.2.2.1 Overview
    • 5.2.2.2 Top Products / Product Portfolio
    • 5.2.2.3 Top Competitors
    • 5.2.2.4 Target Customers/End-Users
    • 5.2.2.5 Key Personnel
    • 5.2.2.6 Analyst View
  • 5.2.3 Becton, Dickinson and Company
    • 5.2.3.1 Overview
    • 5.2.3.2 Top Products / Product Portfolio
    • 5.2.3.3 Top Competitors
    • 5.2.3.4 Target Customers/End-Users
    • 5.2.3.5 Key Personnel
    • 5.2.3.6 Analyst View
  • 5.2.4 Bluebird bio, Inc.
    • 5.2.4.1 Overview
    • 5.2.4.2 Top Products / Product Portfolio
    • 5.2.4.3 Top Competitors
    • 5.2.4.4 Target Customers/End-Users
    • 5.2.4.5 Key Personnel
    • 5.2.4.6 Analyst View
  • 5.2.5 Castle Creek Biosciences, Inc. (Fibrocell Technologies, Inc.)
    • 5.2.5.1 Overview
    • 5.2.5.2 Top Products / Product Portfolio
    • 5.2.5.3 Top Competitors
    • 5.2.5.4 Target Customers/End-Users
    • 5.2.5.5 Key Personnel
    • 5.2.5.6 Analyst View
  • 5.2.6 Dendreon Pharmaceuticals LLC
    • 5.2.6.1 Overview
    • 5.2.6.2 Top Products / Product Portfolio
    • 5.2.6.3 Top Competitors
    • 5.2.6.4 Target Customers/End-Users
    • 5.2.6.5 Key Personnel
    • 5.2.6.6 Analyst View
  • 5.2.7 Helixmith Co., Ltd (ViroMed Co., Ltd)
    • 5.2.7.1 Overview
    • 5.2.7.2 Top Products / Product Portfolio
    • 5.2.7.3 Top Competitors
    • 5.2.7.4 Target Customers/End-Users
    • 5.2.7.5 Key Personnel
    • 5.2.7.6 Analyst View
  • 5.2.8 Gilead Sciences (Kite Pharma)
    • 5.2.8.1 Overview
    • 5.2.8.2 Top Products / Product Portfolio
    • 5.2.8.3 Top Competitors
    • 5.2.8.4 Target Customers/End-Users
    • 5.2.8.5 Key Personnel
    • 5.2.8.6 Analyst View
  • 5.2.9 Kolon TissueGene, Inc.
    • 5.2.9.1 Overview
    • 5.2.9.2 Top Products / Product Portfolio
    • 5.2.9.3 Top Competitors
    • 5.2.9.4 Target Customers/End-Users
    • 5.2.9.5 Key Personnel
    • 5.2.9.6 Analyst View
  • 5.2.10 Novartis AG
    • 5.2.10.1 Overview
    • 5.2.10.2 Top Products / Product Portfolio
    • 5.2.10.3 Top Competitors
    • 5.2.10.4 Target Customers/End-Users
    • 5.2.10.5 Key Personnel
    • 5.2.10.6 Analyst View
  • 5.2.11 Orchard Therapeutics plc
    • 5.2.11.1 Overview
    • 5.2.11.2 Top Products / Product Portfolio
    • 5.2.11.3 Top Competitors
    • 5.2.11.4 Target Customers/End-Users
    • 5.2.11.5 Key Personnel
    • 5.2.11.6 Analyst View
  • 5.2.12 Pfizer Inc.
    • 5.2.12.1 Overview
    • 5.2.12.2 Top Products / Product Portfolio
    • 5.2.12.3 Top Competitors
    • 5.2.12.4 Target Customers/End-Users
    • 5.2.12.5 Key Personnel
    • 5.2.12.6 Analyst View
  • 5.2.13 Renova Therapeutics
    • 5.2.13.1 Overview
    • 5.2.13.2 Top Products / Product Portfolio
    • 5.2.13.3 Top Competitors
    • 5.2.13.4 Target Customers/End-Users
    • 5.2.13.5 Key Personnel
    • 5.2.13.6 Analyst View
  • 5.2.14 Vericel Corporation
    • 5.2.14.1 Overview
    • 5.2.14.2 Top Products / Product Portfolio
    • 5.2.14.3 Top Competitors
    • 5.2.14.4 Target Customers/End-Users
    • 5.2.14.5 Key Personnel
    • 5.2.14.6 Analyst View

6. Research Methodology

List of Figures

• Figure: Global Cell and Gene Therapy Drug Delivery Market (by Therapy Types), $Billion, 2024 and 2035
• Figure: Global Cell and Gene Therapy Drug Delivery Market (by Delivery Methods), $Billion, 2024 and 2035
• Figure: Global Cell and Gene Therapy Drug Delivery Market (by Region), $Billion, 2024 and 2035
• Figure: Global Cell and Gene Therapy Drug Delivery Market Key Trends, Analysis

List of Tables

• Table: Global Cell and Gene Therapy Drug Delivery Market Dynamics, Impact Analysis
• Table: Global Cell and Gene Therapy Drug Delivery Market (by Region), $Billion, 2024-2035